A large and growing clinical need

Lung cancer remains the leading cause of cancer-related death worldwide, with around 2 million new cases annually, the majority being NSCLC.

Approximately 1 million patients receive platinum-based chemotherapy each year, and an increasing proportion are treated with combination regimens that include immune checkpoint inhibitors - creating a substantial opportunity for biomarker-guided treatment decisions.

The research collaboration with the Icahn School of Medicine at Mount Sinai in New York is to evaluate its gene-expression biomarker, Platin-DRP®, in patients with advanced non-small cell lung cancer (NSCLC) treated with platinum chemotherapy in combination with immunotherapy.

"Platinum chemotherapy combined with immunotherapy is a cornerstone of treatment in advanced NSCLC, but better tools are needed to guide patient selection," said Fred R. Hirsch, MD, PhD, Professor and Executive Director, Center for Thoracic Oncology, Mount Sinai Tisch Cancer Center in New York. "We will investigate whether Platin-DRP® is associated with survival, with the aim of enabling more individualized treatment strategies."

"We're moving from trial-and-error toward prediction," said Peter Buhl Jensen, CEO of CHOSA Oncology. "This study evaluates Platin-DRP® in the most important current, treatment setting in lung cancer and could help identify which patients truly benefit from chemo-immunotherapy."

Beyond trial-and-error treatment

The study will investigate whether Platin-DRP® can predict which patients benefit from platinum-based chemotherapy (cisplatin or carboplatin) when combined with PD-1/PD-L1 inhibitors. By leveraging existing data and tissue samples, the study is designed to deliver results in a cost- and time-efficient manner.

Building on strong prior data

The collaboration builds on previously reported results from studies conducted with ETOP and EORTC, where Platin-DRP® demonstrated clinically meaningful stratification of patients, with substantial differences in survival between biomarker-defined groups.

Notably, prior findings show that 50% really benefit with increased survival but also that up to 50% of patients may derive limited or no benefit from platinum-based chemotherapy - those patients should be guided to alternatives. CHOSA's Platin-DRP® is designed to address this gap by identifying patients most likely to benefit - a major unmet need in one of the most widely used cancer treatment classes.

Study collaboration framework

Under the agreement, Mount Sinai will provide access to de-identified tumor samples and clinical data, while CHOSA will perform gene-expression profiling and calculate Platin-DRP® scores.

The study is expected to generate data supporting the continued clinical and commercial development of Platin-DRP® as important tool in immunotherapy in lung cancer and potentially other cancer indications. Platin is the most important therapeutic partner in the immunotherapy 100 billion USD market and guidance towards better outcome is highly needed.

The study with Mount Sinai remains fully funded, supported by a robust capital base and ongoing investor confidence.

For more information please contact:

Peter Buhl Jensen, VD

[email protected]

+ 45 21 60 89 22

About the Icahn School of Medicine at Mount Sinai

The Icahn School of Medicine at Mount Sinai is internationally renowned for its outstanding research, educational, and clinical care programs. It is the sole academic partner for the seven member hospitals* of the Mount Sinai Health System, one of the largest academic health systems in the United States, providing care to New York City's large and diverse patient population. 

The Icahn School of Medicine at Mount Sinai offers highly competitive MD, PhD, MD-PhD, and master's degree programs, with enrollment of more than 1,200 students. It has the largest graduate medical education program in the country, with more than 2,700 clinical residents and fellows training throughout the Health System. The Graduate School of Biomedical Sciences offers 13 degree-granting programs, conducts innovative basic and translational research, and trains more than 4705 postdoctoral research fellows.

Ranked 11th nationwide in National Institutes of Health (NIH) funding, the Icahn School of Medicine at Mount Sinai is among the 90th percentile of U.S. private medical schools in Sponsored Programs Direct Expenditures per Principal Investigator, according to the Association of American Medical Colleges.  More than 6,900 scientists, educators, and clinicians work within and across dozens of academic departments and multidisciplinary institutes with an emphasis on translational research and therapeutics. Through Mount Sinai Innovation Partners (MSIP), the Health System facilitates the real-world application and commercialization of medical breakthroughs made at Mount Sinai.

* Mount Sinai Health System member hospitals: The Mount Sinai Hospital; Mount Sinai Brooklyn; Mount Sinai Morningside; Mount Sinai Queens; Mount Sinai South Nassau; Mount Sinai West; and New York Eye and Ear Infirmary of Mount Sinai.  

About Platin-DRP, a test to predict if cisplatin treatment is likely to be successful

CHOSA is focused on its Platin-DRP® drug response predictor, to which it holds worldwide rights. Platin-DRP is a validated test designed to help identify patients most likely to benefit from cis- and carboplatin treatment. Breast: Strong phase 2b data in metastatic breast cancer have shown that patients selected by DRP® responded better to treatment, had longer progression-free survival, and may also have achieved longer overall survival than patients identified as unlikely to respond well. Lung: Platin-DRP has also demonstrated its ability to predict the benefit of adjuvant cisplatin in lung cancer. Cisplatin treatment after surgery remains a gold standard that can improve cure rates, but doctors have not had a validated tool to identify which patients are most likely to benefit. This is where Platin-DRP may become a game changer, particularly in newer neoadjuvant settings where immunotherapy has shown high efficacy in combination with platinum doublets. Platin-DRP was validated in a blinded retrospective study in two lung cancer patient cohorts receiving cisplatin after surgery to eliminate residual tumour cells. Patients with the 10% highest scores had a 3-year survival of 90%, whereas patients with the lowest 10% scores had a 3-year survival of only 40%¹. In 2026 CHOSA in collaboration with key opinion leaders in lung cancer showed the Platin-DRP in advanced clearly separated the patient with a sensitive cancer from a platin resistant tumor with a median survival of 16.9 months in the former group vs only 5.5 months in the latter2.  

Immunotherapy Cisplatin and carboplatin have shown to activate the immune system, potentially making "cold" tumours more susceptible to PD-1/ PD-L1 inhibitors. This synergy may be important not only in lung cancer, but also in breast cancer, bladder cancer and head & neck cancer. In the growing PD-1/PD-L1 inhibitor market, CHOSA's approach may offer the ability to predict whether platin can provide synergy with PD-L1 inhibition, potentially creating a meaningful advantage for treatment selection and future partners.

1) Buhl et al PLOS One doi: 10.1371/journal.pone0194609 2) ESMO Open Volume 11, Supplement 3, 106773, April 2026

DRP® is a registered trademark of Allarity Therapeutics, Inc., and is used under license granted to CHOSA. LiPlaCis is in-licensed from Allarity Therapeutics Ltd (previous Oncology Venture ApS) and LiPlasome Pharma ApS.